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Abstract: Magnesium gluconate is a pharmaceutical/nutraceutical compound used as a source of magnesium ion. The recent 
study described the impact of The Trivedi Effect®-Energy of Consciousness Healing Treatment on magnesium gluconate for the 
variation in physicochemical, structural, thermal and behavioral properties using PXRD, PSD, FT-IR, UV-vis spectroscopy, TGA, 
and DSC analysis. Magnesium gluconate was divided into two parts – one part was control without any Biofield Energy 
Treatment, while another part was treated with The Trivedi Effect®-Energy of Consciousness Healing Treatment remotely by 
twenty renowned Biofield Energy Healers and defined as The Trivedi Effect® Treated sample. The PXRD analysis exhibited that 
the crystallite size of the treated sample was remarkably altered from -70% to 130% compared with the control sample. The 
average crystallite size was significantly decreased by 23.74% in the treated sample compared to the control sample. Biofield 
Energy Healing Treatment significantly reduced the particle size of magnesium gluconate at d10, d50, and d90 values by 12.15%, 
8.98% and 15.35%, respectively compared to the control sample. The surface area analysis showed that surface area of the treated 
sample was significantly increased by 11.76% compared with the control sample. The FT-IR and UV-vis analysis displayed that 
structure of the magnesium gluconate persisted identical in both the treated and control samples. The TGA analysis exhibited four 
steps thermal degradation in both samples and the total weight loss of the Biofield Energy Treated sample was reduced by 0.19% 
compared with the control sample. The melting temperature of the Biofield Energy Treated sample (171.25ºC) was slightly 
(0.16%) higher from the control sample (170.97ºC). The latent heat of fusion was significantly decreased by 7.76% in the treated 
sample compared to the control sample. The TGA and DSC analysis revealed that the thermal stability of the treated sample was 
enhanced compared with the control sample. The current study revealed that The Trivedi Effect®-Energy of Consciousness 
Healing Treatment might produce a new polymorphic form of magnesium gluconate, which could be more soluble and 
bioavailable along with improved thermal stability compared with the untreated compound. The Biofield Treated sample could be 
more stable during manufacturing, delivery or storage conditions than the untreated sample. Hence, The Trivedi Effect® Treated 
magnesium gluconate would be very useful to design better nutraceutical/pharmaceutical formulations that might offer better 
therapeutic responses against inflammatory diseases, immunological disorders, stress, aging, and other chronic infections. 
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1. Introduction 
Magnesium gluconate is a classical 
nutraceutical/pharmaceutical compound as a source of 
magnesium ion, which is the vital element for more than 300 
enzymes, DNA and RNA synthesis, reproduction and protein 
synthesis and also a vital coherent controller of glycolysis 
and the Krebs cycle in our body [1-3]. Magnesium gluconate 
is widely used for magnesium supplementation in 
hypomagnesemia. Magnesium gluconate is used for the 
prevention and treatment of several diseases, such as cancer, 
diabetes mellitus, allergies, septic shock, inflammatory 
diseases, immunological disorders, asthma, arrhythmias, 
acute myocardial infarction, gestational hypertension, 
preeclampsia, eclampsia, hearing loss, oxidative stress 
induced ischemia/reperfusion injury, etc. [4-10]. Magnesium 
gluconate can be used as an oral tocolytic agent [11], 
neuroprotective [12], and also used in a skin-tightening 
cosmetic composition [13]. Scientific literature demonstrated 
that magnesium gluconate is a potent antioxidant agent and is 
more physiologically acceptable salt with providing highest 
level of magnesium among the other commercially available 
magnesium salts such as chloride, sulfate, citrate, lactate, 
aspartate, etc. [4, 5, 14]. In this point of view, a novel 
proprietary herbomineral formulation was designed as a 
nutraceutical supplement, and can be used for the prevention 
and treatment of various human disorders. Magnesium 
gluconate is one of the components in this novel proprietary 
herbomineral formulation as the source of magnesium. 
Since ancient times, many different cultures, religions, and 
systems of belief have recognized a living force that 
preserves and inhabits every living organism. This force is 
the source of ‘life’ and has been called various names, such 
as prana by the Hindus, qi or chi by the Chinese, and ki by 
the Japanese. This is believed to co-relate with the soul, spirit 
and mind. This hypothetical vital force has been scientifically 
evaluated and is now considered the Bioenergetics Field. The 
Biofield Energy is a dynamic electromagnetic field 
surrounding the human body, resulting from the continuous 
emission of low-level light, heat, and acoustical energy from 
the body. Biofield Energy is infinite, paradimensional and 
can freely flow between the human and environment [15]. 
Thus, a human has the ability to harness energy from the 
ionosphere of the earth, the “universal energy field”, and 
transmit it to any living organism(s) or nonliving object(s) 
around the globe. The object or recipient always receives the 
energy and responds in a useful way. This process is known 
as The Trivedi Effect® - Biofield Energy Healing Treatment 
[16, 17]. Biofield (Putative Energy Field) based Energy 
Therapies are used worldwide to promote health and healing. 
The National Center of Complementary and Integrative 
Health (NCCIH) has recognized and accepted Biofield 
Energy Healing as a Complementary and Alternative 
Medicine (CAM) health care approach in addition to other 
therapies, medicines and practices such as natural products, 
deep breathing, yoga, Tai Chi, Qi Gong, 
chiropractic/osteopathic manipulation, meditation, massage, 
special diets, homeopathy, progressive relaxation, guided 
imagery, acupressure, acupuncture, relaxation techniques, 
hypnotherapy, healing touch, movement therapy, pilates, 
rolfing structural integration, mindfulness, Ayurvedic 
medicine, traditional Chinese herbs and medicines, 
naturopathy, essential oils, aromatherapy, Reiki, cranial 
sacral therapy and applied prayer (as is common in all 
religions, like Christianity, Hinduism, Buddhism and 
Judaism) [18]. Biofield Energy Healing Treatment (The 
Trivedi Effect®) has been published in numerous peer-
reviewed science journals due to its significant impacts in the 
science fields of medical [19], biotechnology [20, 21], 
genetics [22, 23], microbiology [24-26], materials science 
[27, 28], agriculture [29, 30], pharmaceuticals [31, 32], 
nutraceuticals [33, 34], organic compounds [35, 36]. These 
publications reported that Biofield Energy Treatment (The 
Trivedi Effect®) has the significant capability to alter the 
physical, structural, chemical, thermal, and behavioral 
properties of the wide varieties of living and non-living 
substances. Although magnesium gluconate displayed 
highest bioavailability and moderate solubility in water in 
comparison to other magnesium salts, humans still face 
problems in achieving their daily requirements of magnesium 
[37]. The physical and chemical properties such as particle 
size, crystalline structure, crystallite size, surface area, etc. of 
a pharmaceutical have a direct influence on the absorption, 
dissolution, and bioavailability of the drug [38]. The stability 
of a solid drug with respect to the atmospheric conditions is 
very important to the pharmaceutical industry during 
processing, formulation, storage, and packaging in order to 
achieve better therapeutic efficacy [39]. Biofield Energy 
Treatment (The Trivedi Effect®) has been reported to change 
the particle size, specific surface area, crystalline, chemical 
and thermal behavior of an atom/ion through possible 
mediation of neutrinos [40]. Scientific literature mentions 
that powder X-ray diffraction (PXRD), particle size 
distribution analysis (PSD), Fourier transform infrared (FT-
IR) spectrometry, ultraviolet-visible (UV-vis) spectroscopy, 
thermogravimetric analysis (TGA), and differential scanning 
calorimetry (DSC) analysis play an vital role for solving 
various problems encountered in industries for the 
pharmaceutical/nutraceutical formulation and developments 
[41]. By considering these aspects, the physicochemical, 
structural, thermal, and behavioral properties of the Biofield 
Energy Treated and untreated magnesium gluconate were 
studied using various analytical techniques including PXRD, 
PSD, FT-IR, UV-vis spectroscopy, TGA, and DSC. 
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2. Materials and Methods 
2.1. Chemicals and Reagents 
Magnesium gluconate hydrate was procured from Tokyo 
Chemical Industry Co., Ltd. (TCI), Japan. All other 
chemicals used in the experiment were of analytical grade 
available in India.  
2.2. Energy of Consciousness Treatment Strategies 
Magnesium gluconate was one of the components of the 
new proprietary herbomineral formulation, which was 
developed by our research team and was used per se as the test 
compound for the current study. The test compound was 
divided into two parts, one part of the test compound did not 
receive any sort of treatment and was defined as the untreated 
or control magnesium gluconate sample. The second part of 
the test compound was designated as the Biofield Energy 
Treated or The Trivedi Effect® Treated sample, which was 
received The Trivedi Effect®-Energy of Consciousness 
Healing Treatment (Biofield Energy Healing Treatment) by a 
group of twenty renowned Biofield Energy Healers remotely. 
Fifteen Biofield Energy Healers were remotely located in the 
U. S. A., two in Canada, one in the UK, one in Australia, and 
one in Germany. The test compound was located in the 
research laboratory of GVK Biosciences Pvt. Ltd., Hyderabad, 
India. The Trivedi Effect® - Energy of Consciousness Healing 
Treatment was provided for 5 minutes through the Healer’s 
Unique Energy Transmission process remotely to the test 
compound, which was kept under laboratory conditions. None 
of the Biofield Energy Healers in this study visited the 
laboratory in person, nor had any contact with the compounds. 
Similarly, the control compound was subjected to “sham” 
healer for 5 minutes, under the same laboratory conditions. 
The sham healer did not have any knowledge about the 
Biofield Energy Treatment. After that, the Biofield Energy 
Treated and untreated samples were kept in similar sealed 
conditions and characterized thoroughly by PXRD, PSD, FT-
IR, UV-visible spectroscopy, TGA, and DSC analysis.  
2.3. Characterization 
2.3.1. Powder X-ray Diffraction (PXRD) Analysis 
The PXRD analysis was performed on PANalytical X’Pert 
Pro powder X-ray diffractometer system. The X-ray of 
wavelength of 1.54056 Å was used. The data was collected in 
the form of a chart of the Bragg angle (2θ) vs. intensity, and a 
detailed table containing information on peak intensity counts, d 
value (Å), relative intensity (%), full width half maximum 
(FWHM) (θ°). From the XRD results, the crystallite size (G) 
was calculated using X’Pert data collector and X’Pert high score 
plus processing software. The crystallite size (G) was calculated 
from the Scherrer equation [42, 43]. The method was based on 
the width of the diffraction patterns obtained in the X-ray 
reflected crystalline region. The crystallite size (G) was 
calculated by using the following formula 1: 
G	 = 	kλ/(bCosθ)                                      (1) 
Where, k is the equipment constant (0.5), λ is the X-ray 
wavelength (0.154 nm); b in radians is the full-width at half 
of the peaks and θ is the corresponding Bragg angle. 
Percent change in crystallite size (G) was calculated using 
the following equation 2: 
%	change	in	crystallite	size	 =
	 !"#	$%&!%'(
	$%&!%'
× 100  (2) 
Where GControl and GTreated are the crystallite size of the 
control and Biofield Energy Treated samples, respectively. 
A total of ~500.18 mg of the control and Biofield Energy 
Treated samples individually were used for the analysis and 
prepared by the back loading technique using the sample 
preparation kit. The sample was spread on the holder ring in 
sufficient quantity to fill the ring cavity. It was then pressed 
down using a powder press block and scrapped the powder 
that was in surplus using a glass slide in order to get a 
densely packed specimen. The bottom plate was placed onto 
the holder ring and clamped in position. The sample holder 
was then removed from the sample preparation table by 
turning it upside down. A smooth surface of the sample was 
obtained to ensure optimum results. 
2.3.2. Particle Size Distribution (PSD) Analysis 
The average particle size and particle size distribution were 
analyzed using Malvern Mastersizer 2000, UK, with a detection 
range from 0.01 µm to 3000 µm. The sample unit was filled 
with dispersant medium and operated the stirrer at 2500 rpm. 
Alignment of the optics was done and taken the background 
measurement. After the background measurement, the sample 
was added in to the sample unit with constant monitoring of the 
obscuration. When the obscuration of the sample reached in 
between 15% and 20%, further addition of the sample stopped. 
When the obscuration was stable, the measurement was taken 
twice and the average was taken of the two measurements. The 
average histogram of the two measurements was recorded. The 
printout of the average histogram of the two measurements were 
documented in this study. Along with histogram, the data was 
presented in a table format which includes particle size (µm). 
Also, the values at below 10% level (d10), 50% level (d50), and 
90% level (d90) were calculated from the histogram, and the 
calculations such as surface area (m2/g) were done by using 
Mastersizer 2000 software. The percent change in particle size 
(d) for at below 10% level (d10), 50% level (d50), and 90% level 
(d90) was calculated using the following equation 3: 
%	change	in	particle	size =
- !"#-$%&!%'(
-$%&!%'
× 100    (3) 
Where, dControl and dTreated are the particle size (µm) for at 
below 10% level (d10), 50% level (d50), and 90% level (d90) of 
the control and Biofield Energy Treated samples, 
respectively. 
The percent change in surface area (S) was calculated 
using the following equation 4: 
%	change	in	surface	area =
0	 !"#0	$%&!%'(
0	$%&!%'
× 100  (4) 
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Where, SControl and STreated are the surface area of the 
control and Biofield Energy Treated samples, respectively. 
2.3.3. Fourier Transform Infrared (FT-IR) Spectroscopy  
FT-IR spectroscopy of the magnesium gluconate was 
performed using Spectrum Two (Perkin Elmer, USA) Fourier 
Transform Infrared Spectrometer with the frequency range of 
400-4000 cm-1 by using the pressed KBr disk technique. 
2.3.4. Ultraviolet-Visible Spectroscopy (UV-Vis) Analysis 
The UV-Vis spectral analysis was carried out using 
Shimadzu UV-2450 with UV Probe, Japan. The spectrum 
was recorded using 1 cm quartz cell with a slit width of 1.0 
nm. The wavelength range chosen for recording the spectra 
was 190-800 nm. The absorbance spectra (in the range of 0.2 
to 0.9) and absorbance maximum (λmax) were recorded. 
2.3.5. Thermal Gravimetric Analysis (TGA) 
The TGA analysis was performed using TGA Q50 (TA 
Instruments, USA) at a heating rate of 10ºC/min from room 
temperature i.e. 25°C to 900°C in a nitrogen atmosphere. A 
total of ~15 mg of sample was weighed in a platinum 
crucible. In TGA, the weight loss for each step was recorded 
in grams as well as in percent loss with respect to the initial 
weight. Also, the onset, endset, and peak temperature for 
each step were recorded in TGA.  
Percent change in weight loss (W) was calculated using 
the following equation 5: 
%	change	in	weight	loss 
2	 !"#2	$%&!%'(
2	$%&!%'
) 100    (5) 
Where WControl and WTreated are the weight loss of the 
control and Biofield Energy Treated samples, respectively. 
2.3.6. Differential Scanning Calorimetry (DSC)
 
 
Analysis was performed using the DSC Q20 (TA Instruments, 
USA) Differential Scanning Calorimeter. A total of ~8.23 mg of 
sample was weighed and sealed in an aluminum pan and 
equilibrated at 25 °C and heated up to 450ºC at the heating rate 
of 10ºC/min under nitrogen gas as purge atmosphere with the 
flow rate of 50 mL/min. The value for onset, endset, peak 
temperature, peak height (mJ or mW), peak area, and change in 
heat (J/g) for each peak were recorded. 
The percent change in melting point (T) was calculated 
using the following equation 6: 
%	change	in	melting	point 
4 !"#4$%&!%'(
4$%&!%'
) 100     (6) 
Where, TControl and TTreated are the melting point of the 
control and Biofield Energy Treated samples, respectively. 
The percent change in the latent heat of fusion (∆H) was 
calculated using the following equation 7: 
%	change	in	latent	heat	of	fusion 
56 !"#76$%&!%'(
76$%&!%'
)
100                                      (7) 
Where ∆HControl and ∆HTreated are the latent heat of fusion of 
the control and Biofield Energy Treated samples, 
respectively. 
3. Results and Discussions 
3.1. Powder X-ray Diffraction (PXRD) Analysis  
The PXRD diffractograms of both the control and Biofield 
Energy Treated magnesium gluconate are shown in Figure 1. 
The diffractograms exhibited sharp and intense peaks 
indicating that both the samples were crystalline in nature. 
PXRD data such as the Bragg angle (2θ), relative intensity 
(%), full width half maximum (FWHM) (θ°), and crystallite 
size (G) for the control and Biofield Energy Treated 
magnesium gluconate are presented in Table 1.  
 
Figure 1. Powder X-ray diffractograms of the control and Biofield Energy Treated magnesium gluconate.  
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Table 1. PXRD data for the control and Biofield Energy Treated magnesium gluconate. 
Entry No. 
Bragg angle (°2θ) Relative Intensity (%) FWHM (°2θ) Crystallite size (G, nm) 
Control Treated  Control Treated  Control Treated  Control Treated  % change* 
1 5.06 5.07 100.00 100.00 0.0836 0.0836 52.70 52.70 0.00 
2 9.88 9.89 38.60 32.64 0.0836 0.1004 52.84 44.00 -16.73 
3 13.90 13.91 39.88 35.20 0.1171 0.1338 37.87 33.14 -12.48 
4 15.83 15.84 26.42 24.35 0.1338 0.1338 33.21 33.21 0.00 
5 16.37 16.39 16.83 13.30 0.1004 0.1004 44.29 44.29 0.00 
6 17.90 17.92 55.85 47.75 0.2175 0.1836 20.49 24.27 18.47 
7 18.48 18.49 80.29 71.48 0.1171 0.1632 38.08 27.33 -28.25 
8 19.01 19.01 65.26 53.17 0.1673 0.2448 26.68 18.23 -31.66 
9 20.08 20.10 22.21 17.51 0.1506 0.1836 29.68 24.35 -17.97 
10 20.93 20.95 29.75 24.34 0.1338 0.1632 33.45 27.43 -18.01 
11 22.38 22.40 53.21 43.27 0.1673 0.2040 26.82 22.00 -17.99 
12 23.62 23.65 49.88 40.37 0.1840 0.1632 24.44 27.56 12.75 
13 24.72 24.73 23.84 17.44 0.0836 0.1428 53.90 31.56 -41.46 
14 25.47 25.53 18.86 12.78 0.1338 0.1224 33.73 36.87 9.33 
15 27.38 27.38 40.39 34.02 0.0669 0.2244 67.72 20.19 -70.19 
16 29.33 29.32 36.46 28.83 0.0669 0.2040 68.02 22.31 -67.21 
17 31.43 31.43 24.38 19.45 0.1673 0.1836 27.34 24.91 -8.88 
18 31.89 31.88 22.16 17.34 0.1506 0.2040 30.40 22.44 -26.18 
19 34.55 34.54 17.84 16.62 0.1004 0.1224 45.92 37.67 -17.98 
20 35.72 35.74 31.36 25.34 0.1506 0.1836 30.71 25.19 -17.97 
21 37.61 37.63 24.18 19.60 0.1171 0.1428 39.72 32.57 -17.99 
22 38.90 38.88 20.20 15.07 0.1673 0.2040 27.91 22.89 -18.00 
23 39.64 39.67 34.87 25.76 0.0669 0.1632 69.96 28.68 -59.00 
24 40.44 40.44 35.83 31.18 0.0669 0.1020 70.13 46.00 -34.41 
25 41.77 41.82 21.93 15.98 0.2007 0.3672 23.48 12.84 -45.33 
26 44.13 44.16 26.20 21.11 0.2342 0.1020 20.29 46.58 129.63 
27 49.30 49.30 15.20 10.46 0.1338 0.2040 36.21 23.75 -34.41 
Average crystallite size 39.48 30.11 -23.74 
FWHM: Full width half maximum, *denotes the percentage change in the crystallite size of the Biofield Energy Treated sample with respect to the control 
sample. 
The crystallite size was calculated using Scherrer equation 
[42, 43]. The highest intense peak (100% relative intensity) in 
both the control and Biofield Energy Treated samples was 
observed at Bragg’s angle (2θ) equal to 5.06 and 5.07°, 
respectively (Table 1, entry 1). Table 1 showed that 2θ of the 
both samples remained almost same in other XRD peaks, but the 
relative intensities of the peaks and crystallite size in the Biofield 
Energy Treated sample was found significantly different from 
the control sample. The crystallite sizes of the control and 
Biofield Energy Treated magnesium gluconate hydrate at 
position 2θ equal to nearly 5.1°, 15.8°, and 16.4° (Table 1, entry 
1, 4, and 5) remained unchanged. Consequently, the crystallite 
size values of the Biofield Energy Treated sample at 2θ equal to 
nearly 9.88°, 13.9°, 18.5°, 19.0°, 20.1°, 20.9°, 22.4°, 24.7°, 
27.4°, 29.3°, 31.4°, 31.9°, 34.5°, 35.7°, 37.6°, 38.9°, 39.6°, 
40.4°, 41.8°, and 49.3° (Table 1, entry 2, 3, 7-11, 13, 15-25, and 
27) were significantly decreased from 9% to 70% with respect 
to the control sample. Furthermore, the crystallite sizes of the 
control and Biofield Energy Treated magnesium gluconate at 2θ 
equal to nearly 17.9°, 23.6°, 25.5°, and 44.2° (Table 1, entry 6, 
12, 14, and 26) were significantly increased from 9% to 130% in 
the Biofield Energy Treated sample in comparison to the control 
sample. The average particle size of the Biofield Energy Treated 
sample was significantly decreased by 23.74% compared to the 
control sample. Scientific literature reported that the changes in 
the XRD patterns, such as crystallite size and relative intensities, 
indicated the modification of the morphology of the crystal as 
well as the proof of polymorphic transition [44-46]. As the 
crystal morphology of the Biofield Energy Treated sample was 
altered compared with the control sample, the Biofield Energy 
Treated sample might be a new polymorphic form of 
magnesium gluconate. The crystal pattern, size and even 
polymorphic form of a pharmaceutical plays an important role in 
drug solubility, dissolution and bioavailability. It has been 
reported in the literature that the alteration in crystal morphology 
has significant impact on the in vitro dissolution rate, which is 
related with the bioavailability of orally administered 
pharmaceutical/nutraceutical [39]. Thus, it can be concluded that 
the Biofield Energy Healing Treatment might be a very useful 
method for enhancing the bioavailability of magnesium 
gluconate. 
3.2. Particle Size Distribution (PSD) Analysis 
The particle size values at d10, d50, and d90 values and 
surface area of both the control and Biofield Energy Treated 
magnesium gluconate were examined and the results are 
represented in Table 2.  
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Table 2. Particle size data (d10, d50, and d90) and surface area of the control 
and Biofield Energy Treated magnesium gluconate. 
Test Item 
d10 
(µm) 
d50 
(µm) 
d90 
(µm) 
Surface 
area (m
2/g) 
Control  7.16 43.00 189.09 0.34 
Biofield Energy Treated 6.29 39.14 160.06 0.38 
Percent change* (%)  -12.15 -8.98 -15.35 11.76 
*denotes the percentage change in the particle size data (d10, d50, and d90) and 
surface area of the Biofield Energy Treated sample with respect to the 
control sample. 
The control sample showed a particle size values of d10 
(7.16 µm), d50 (43.00 µm), and d90 (189.09 µm). After the 
Biofield Energy Healing Treatment, the particle size values 
of magnesium gluconate were found as 6.29, 39.14, and 
160.06 µm for d10, d50, and d90, respectively. Thus, Biofield 
Energy Treatment lowered significantly the particle size 
values of d10, d50, and d90 values of magnesium gluconate by 
12.15%, 8.98% and 15.35%, respectively with respect to the 
control sample. The surface area analysis of both control and 
Biofield Energy Treated magnesium gluconate hydrate as 
shown in the Table 2 demonstrated that the surface area of 
the Biofield Energy Treated sample (0.38 m2/g) was 
significantly increased by 11.76% from the control sample 
(0.34 m2/g) as shown in Table 2.  
Poorly crystallized compounds possess more surface area 
and higher exchange capacities than well-crystallized 
compounds [47]. In addition, the variation of the crystal 
morphology in the Biofield Energy Treated sample, which 
was well-supported from PXRD data, may cause to alter the 
surface area of the Biofield Energy Treated magnesium 
gluconate in comparison with the control sample. It has been 
well established that the particle size, shape and surface area 
of pharmaceutical compounds have an important impact on 
solubility, dissolution and in vivo bioavailability, as well as 
in helping the design of new drug delivery systems [48, 49]. 
Reduced particle size and higher surface area would increase 
the solubility of the solid particles, and consequently would 
improve the dissolution rate and bioavailability [50]. Thus, it 
is assumed that the Biofield Energy Treated magnesium 
gluconate might be dissolved and absorbed at a faster rate 
and may possibly have more bioavailability than normal 
magnesium gluconate.  
3.3. Fourier Transform Infrared (FT-IR) Spectroscopy 
The FT-IR spectra of both the control and Biofield Energy 
Treated magnesium gluconate shown in Figure 2, exhibited 
only one broad band with high intensity at 3398 cm-1, which 
was attributed to the stretching vibrations of the hydroxyl 
groups originating from the water present in the magnesium 
gluconate. The bands of stretching vibrations of primary and 
secondary hydroxyl groups from the gluconate part of the 
compound appeared in this region. These bands were remained 
invisible due to the intensive broad band of water [51].  
The FT-IR spectra of both the control and Biofield Energy 
Treated magnesium gluconate (Figure 2) demonstrated only one 
broad band centroid at 3398 cm-1. This peak was attributed to 
the stretching vibrations of hydroxyl groups due to the water 
present in magnesium gluconate. The primary and secondary 
hydroxyl groups from the gluconate part of magnesium 
gluconate also showed the characteristic bands in this region that 
were remained undetectable due to the intensive broad band of 
water. The absorption peaks for the deformation vibration of the 
primary and secondary hydroxyl groups of the control sample 
were observed at 1434 cm-1 for in-the-plane δ(OH) and 636 and 
578 cm-1 for the out-of-plane γ(OH), whereas these peaks were 
found in the spectrum of the Biofield Energy Treated sample at 
1433, 636 and 577 cm-1. The FT-IR spectra of both the control 
and Biofield Energy Treated samples exhibited C-H stretching at 
2935 and 1381 cm-1. A very sharp and intensive band at 1606 
cm-1 for C=O stretching vibration of a carbonyl group of 
carboxylate anion was noticed in the spectra of both the control 
and Biofield Energy Treated samples. The band of the C-O 
stretching vibrations of the primary alcohol group was found at 
1057 and 1056 cm-1 in the spectra of the control and Biofield 
Energy Treated sample, respectively. The absorption peaks at 
1231 and 1142 cm-1 due to the C-O stretching vibrations of the 
secondary alcohol groups were observed in the spectrum of the 
control sample, whereas the Biofield Energy Treated sample 
showed these C-O stretching vibrations at 1231 and 1141 cm-1. 
As there was no changes observed in the vibrational frequencies 
in both the control and Biofield Energy Treated samples, the 
structural properties of magnesium gluconate was remained 
unaltered after the Biofield Energy Healing Treatment. 
 
Figure 2. FT-IR spectra of the control and Biofield Energy Treated magnesium gluconate. 
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3.4. Ultraviolet-Visible Spectroscopy (UV-Vis) Analysis 
Scientific literature described that 0.1% aqueous solution 
of magnesium gluconate showed a maximum absorption 
peak (λmax) at 194.7 nm [52]. The UV-vis spectra of both the 
control and Biofield Energy Treated samples (Figure 3) 
displayed that the wavelength for the maximum absorbance 
(λmax) of both the control and Biofield Energy Treated 
samples were at 198.0 nm and 198.6 nm, respectively with a 
minor shift of absorbance maxima from 2.2111 (control 
sample) to 2.2056 (Biofield Energy Treated sample). 
 
Figure 3. UV-Vis spectra of the control and Biofield Energy Treated 
magnesium gluconate. 
The UV absorbance happens due to the different types of 
energy transitions from the singlet to the singlet excited state 
such as σ → :∗, = → >∗, ?=@	> → >∗ . These types of 
electronic transitions are happened when the difference in 
energy between the lowest unoccupied molecular orbital 
(LUMO) and the highest occupied molecular orbital 
(HOMO) is significantly higher than the activation energy of 
the compound [53]. The λmax of the Biofield Energy Treated 
sample was slightly (0.30%) higher than the control. It is then 
concluded that the structural configuration or activation 
energy of the Biofield Energy Treated sample was almost 
similar compared with the control sample. 
3.5. Thermal Gravimetric Analysis (TGA) 
The TGA and DSC are widely used analytical techniques 
for investigation of the thermal stabilities of pharmaceutical 
solids, determination of several kinetic parameters, and 
accomplishment of drug/excipient compatibility data for the 
pre-formulation study [54]. The TGA study of both the 
control and the Biofield Energy Treated magnesium 
gluconate (Figure 4) exhibited four thermal degradation steps 
and the data are presented in Table 3.  
Table 3. Thermal degradation steps of the control and Biofield Energy 
Treated magnesium gluconate. 
S. No. Temperature (°C) % Weight loss % Change* 
 
Control Treated Control Treated  
1st step of 
degradation 
69.89 67.40 1.14 1.11 -2.63 
2nd step of 
degradation 
183.02 184.89 8.19 8.26 0.85 
3rd step of 
degradation 
301.13 300.51 38.79 38.77 -0.05 
4th step of 
degradation 
595.77 595.77 21.42 21.27 -0.70 
Total weight 
loss 
- - 69.54 69.41 -0.19 
*denotes the percentage change in the weight loss of the Biofield Energy 
Treated sample with respect to the control sample. 
The weight loss of the Biofield Energy Treated sample at 
the first, second, and fourth steps of thermal degradation 
were decreased by 2.63%, 0.05%, and 0.70%, respectively 
compared to the control sample. Subsequently, the weight 
loss of the Biofield Energy Treated magnesium gluconate at 
the third step of degradation was increased by 0.85% 
compared to the control sample. The first step degradation 
was probably associated with the elimination of water in both 
the samples.  
 
Figure 4. TGA thermograms of the control and Biofield Energy Treated 
magnesium gluconate. 
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The total weight loss was 69.54% and 69.41% in the 
control and Biofield Energy Treated samples, respectively 
from their initial weight from room temperature to 600°C 
(Table 3). Thus, the total weight loss of the Biofield Energy 
Treated sample was reduced by 0.19% compared with the 
control sample.  
3.6. Differential Scanning Calorimetry (DSC) Analysis 
The DSC thermograms of both the control and Biofield 
Energy Treated magnesium gluconate (Figure 5) showed two 
endothermic peaks. Their DSC data are presented in Table 4. 
The first broad endothermic (minor) peak was due to the 
removal of water from the sample. The second sharp 
endothermic (major) peak was due to the melting temperature 
of the magnesium gluconate.  
 
Figure 5. DSC thermograms of the control and Biofield Energy Treated 
magnesium gluconate. 
The DSC data analysis (Table 4) revealed that the melting 
temperature of the Biofield Energy Treated sample (171.25ºC) 
was slightly (0.16%) higher from the control sample 
(170.97ºC). The latent heat of fusion in the Biofield Energy 
Treated magnesium gluconate was significantly decreased by 
7.76% compared to the control sample (Table 4). 
Table 4. The latent heat of fusion (J/G) and melting point (°C) values of the 
control and Biofield Energy Treated magnesium gluconate. 
Endothermic 
peak 
Description 
Tonset 
(°C) 
Tpeak 
(°C) 
Tendset 
(°C)  
∆Hfusion 
(J/g) 
 Control sample 66.59 86.81 104.15 20.95 
Minor peak 
Biofield 
Treated sample 
63.77 83.20 98.87 16.86 
 % Change* -4.23 -4.16 -5.07 -19.52 
 Control sample 159.16 170.97 200.00 305.60 
Major peak 
Biofield 
Treated sample 
157.80 171.25 200.00 281.90 
 % Change* -0.85 0.16 0.00 -7.76 
Tonset:
 Onset melting temperature, Tpeak: Peak melting temperature, Tendset: 
Endset melting temperature, ∆H: Latent heat of fusion, *denotes the 
percentage change of the Biofield Energy Treated sample with respect to the 
control sample. 
Additionally, the temperature for water removal and the 
latent heat of fusion in the Biofield Energy Treated sample 
was significantly decreased by 4.16% and 19.52%, 
respectively compared with the control sample. Scientific 
literature reported that decreased particle size reduced the 
latent heat of fusion [55]. It is assumed that Biofield Energy 
Healing Treatment might lead to introduce enantiotropic 
form of magnesium gluconate. The Biofield Energy Treated 
sample, having a lower latent heat of fusion, would be a more 
stable and soluble polymorphic form at temperature below 
the transition point [45, 56].  
4. Conclusions 
The current analysis anticipated the significant effect of 
The Trivedi Effect®-Energy of Consciousness Healing 
Treatment (Biofield Energy Healing Treatment) on 
physicochemical, thermal and behavioral properties of 
magnesium gluconate. The PXRD analysis revealed that the 
crystallite size was significantly transformed from -70% to 
130% in The Trivedi Effect® Treated magnesium gluconate 
compared to the control sample. The average crystallite size 
of the Biofield Energy Treated sample was significantly 
reduced by 23.74% compared with the control sample. 
Overall, the PXRD analysis showed that the crystal 
morphology of the Biofield Energy Treated sample was 
significantly changed compared to the control sample. PSD 
analysis revealed that the particle size of magnesium 
gluconate at d10, d50, and d90 values were significantly 
decreased by 12.15%, 8.98% and 15.35%, respectively in 
The Trivedi Effect® Treated sample compared to the control 
sample. The surface area analysis demonstrated that surface 
area of The Trivedi Effect® Treated sample was significantly 
enhanced by 11.76% compared with the control sample. The 
TGA analysis presented four steps thermal degradation of 
both the samples and the total weight loss was decreased by 
0.19% in the Biofield Energy Treated sample compared with 
the control sample. The DSC analysis demonstrated that the 
melting temperature of the Biofield Energy Treated sample 
(171.25ºC) was slightly (0.16%) increased compared with the 
control sample (170.97ºC). The latent heat of fusion of the 
Biofield Energy Treated sample was significantly reduced by 
7.76% compared to the control sample. The TGA and DSC 
analysis clearly indicated that the thermal stability of the 
Biofield Energy Treated sample was improved compared 
with the control sample. Thus, The Trivedi Effect® Treated 
magnesium gluconate would be a new polymorphic form of 
magnesium gluconate, which could be more soluble and 
bioavailable along with improved thermal stability compared 
with the untreated magnesium gluconate. Briefly, The 
Trivedi Effect® - Energy of Consciousness Healing 
Treatment could be a useful approach in the design of better 
nutraceutical and/or pharmaceutical formulations that can 
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offer significant therapeutic responses against various 
diseases such as diabetes, allergies, septic shock, sleep 
disorder, insomnia, anxiety, depression, Attention Deficit 
Disorder, Attention Deficit Hyperactive Disorder, mental 
restlessness (mind chattering), brain frog, low libido, 
impotency, lack of motivation, mood swings, fear of the 
future, confusion, migraines, headaches, forgetfulness, 
overwhelm, loneliness, worthlessness, indecisiveness, 
frustration, irritability, chronic fatigue, obsessive/compulsive 
behavior, panic attacks, Lupus, Systemic Lupus 
Erythematosus, Hashimoto Thyroiditis, Asthma, Chronic 
peptic ulcers, Tuberculosis, Hepatitis, Chronic active 
hepatitis, Celiac Disease (gluten-sensitive enteropathy), 
Addison Disease, Crohn's disease, Graves’ Disease, 
Pernicious and Aplastic Anemia, Sjogren Syndrome, Irritable 
Bowel Syndrome (IBS), Multiple Sclerosis, arthritis, Chronic 
periodontitis, Ulcerative colitis, Chronic sinusitis, 
Myasthenia Gravis, Atherosclerosis, Vasculitis, Dermatitis, 
Diverticulitis, Alopecia Areata, Psoriasis, Scleroderma, 
Fibromyalgia, Chronic Fatigue Syndrome, Vitiligo, 
cardiovascular disease, cancer, Alzheimer’s disease, 
dementia, cataracts, osteoporosis, hypertension, glaucoma, 
hearing loss, Parkinson’s Disease, Huntington’s Disease, 
Prion Disease, Motor Neurone Disease, Spinocerebellar 
Ataxia, Spinal muscular atrophy, Amyotrophic lateral 
sclerosis, Friedreich’s Ataxia, Lewy Body Disease, chronic 
infections and many more. 
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